Search
Tyropanoic acid
go.drugbank.com/drugs/DB09340ApprovedThe molecule contains three heavy iodine atoms which obstruct X-rays in the same way as the calcium in bones, which results in a visible image [L1608]. … Tyropanoic acid is a radiocontrast agent used in cholecystography, the X-ray diagnosis of gallstones under the trade names include Bilopaque, Lumopaque, Tyropaque, and Bilopac.
Categories: Compounds used in a research, industrial, or household settingCyclobenzaprine
go.drugbank.com/drugs/DB00924ApprovedInvestigationalCyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977. … [A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.
Synonyms: N,N-dimethyl-5H-dibenzo(a,d)cycloheptene-Δ5,γ-propylamine, (3-Dibenzo[a,d]cyclohepten-5-ylidene-propyl)-dimethyl-aminePork collagen
go.drugbank.com/drugs/DB14100ApprovedThe surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. … It has been used since 1995 as Carticel and gained biologic license in 1997. The surgical implantation was first performed in Sweden.
Mixtures: Le-Blen Nano Collagen Peptide SerumBriakinumab
go.drugbank.com/drugs/DB05459InvestigationalAs of 2011 drug development for psoriasis has been discontinued in the U.S. and Europe. … Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases.
Lurasidone
go.drugbank.com/drugs/DB08815ApprovedInvestigationalFood and Drug Administration (FDA) for treatment of schizophrenia on October 29, 2010 and is currently pending approval for the treatment of bipolar disorder in the United States. … Lurasidone is an atypical antipsychotic developed by Dainippon Sumitomo Pharma. It was approved by the U.S.
Prasugrel
go.drugbank.com/drugs/DB06209ApprovedInvestigationalSimilar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. … FDA approved in 2009.
Products: PRASUGREL AL 5MG HBR FTA, PRASUGREL AL 10MG HBR FTAAutophagy
smpdb.ca/view/SMP0578913Signalingthe fasted state), calcium/calmodulin‑dependent protein kinase kinase 2 (CAMKK2) directly phosphorylates and activates AMPK, which in turn phosphorylates ULK1 to trigger phagophore formation in an mTOR‑independent … An increased AMP:ATP ratio activates AMPK and concurrently inhibits mTORC1, resulting in dephosphorylation and activation of ULK1 kinase activity to nucleate the phagophore.
Enzymes: Activating molecule in BECN1-regulated autophagy protein 1Bempedoic acid
go.drugbank.com/drugs/DB11936ApprovedInvestigational[L12180] Bempedoic acid is first-in-class adenosine triphosphate-citrate lyase (ACL) inhibitor used once a day for reducing LDL cholesterol levels in statin-refractory patients. … A combination product of bempedoic acid and [ezetimibe] was approved on February 26, 2020 for increased control of LDL cholesterol levels in patients experiencing refractory elevations despite previous
Revumenib
go.drugbank.com/drugs/DB18515ApprovedInvestigationalMenin is a scaffold protein that interacts with both the wild-type and rearranged KMT2A, which is crucial for KMT2A activity and the maintenance of _HOXA_ expression and leukemogenesis. … Abnormal gene rearrangements at chromosome locus 11q23, called KMT2A rearrangements or translocations, are present in 5%-10% of patients with acute leukemias and are the sole genetic aberration found in
Synonyms: Benzamide, n-ethyl-2-((4-(7-((trans-4-((ethylsulfonyl)amino)cyclohexyl)methyl)-2,7-diazaspiro(3.5)non-2-yl)-5-pyrimidinyl)oxy)-5-fluoro-n-(1-methylethyl)-Rivastigmine
go.drugbank.com/drugs/DB00989ApprovedInvestigationalRivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase. … Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type.
Categories: Compounds used in a research, industrial, or household settingProducts: RIVASTIGMIN AL 3MG HART, RIVASTIGMIN AL 6MG HART